A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40kD) (Pegasys®) alone or in combination with lamvudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B - Marcellin,P.; Lau,G.KK.; Bonino,F. (Hepatology, 2003)